Tuberculosis Treatment Drugs Market By Disease Type, By Therapy Type, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2021-2031

List of Tables

The Tuberculosis Treatment Drugs Market valued for $1,929.96 million in 2021 and is estimated to reach $3,243.90 million by 2031, exhibiting a CAGR of 5.3% from 2022 to 2031.

Tuberculosis Treatment Drugs Market - IMG1

Tuberculosis (TB) is an infectious disease caused by the bacterium Mycobacterium tuberculosis. It primarily affects the lungs, but can also affect other parts of the body such as the kidneys, bones, and brain. TB is transmitted through the air when an infected person coughs, sneezes, or talks. It is an airborne disease, which means that it can easily spread from person to person through the inhalation of infected droplets. The diagnosis of TB is typically based on a combination of medical history, physical examination, chest X-ray, and laboratory tests such as sputum microscopy and culture. Moreover, various first line drugs such as isoniazid, rifampin, ethambutol, and others and second line drugs such as cyclosterine, ethioamide, capreomycin, and others are approved and used to treat tuberculosis.

The driving factor for tuberculosis treatment drugs market is rise in prevalence of tuberculosis cases. For instance, according to report of Centers for Disease Control and Prevention (CDC) 2022, it was stated that 7,882 million cases of TB were reported in 2021, i.e. 9.4% increase in TB cases. Thus, rise in prevalence of tuberculosis cases results in high demand for drugs which is expected to drive the growth of market. Further, increase in number of pipeline medications for treating tuberculosis disease that is anticipated to receive regulatory approval in the upcoming years; will drive the growth during the forecast period.

Furthermore, rise in initiatives by non-government & government organizations to increase awareness about the TB disease and available treatments among the patients through different programs and campaigns is predicted to boost the growth of the market. In addition, rise in adoption of advanced technologies to diagnose tuberculosis disease and awareness about the importance of early diagnosis is anticipated to boost the market growth. Moreover, many key players have adopted key strategies such as collaboration, agreement, or alliance to increase their market presence in the global tuberculosis treatment drugs market, which is expected to drive the growth of the market.

However, factors such as major side effects associated with tuberculosis drugs may restrain the growth of tuberculosis treatment drugs market. In addition, increase in extensive drug resistance can hamper the growth of the market.

Moreover, rise in demand for novel therapeutics for treating tuberculosis and strong presence of pipeline molecules along with rise in regulatory approvals for new therapeutics is expected to offer lucrative opportunities to key players of market.

The global tuberculosis treatment drugs market is segmented into disease type, therapy type, distribution channel, and region. On the basis of disease type, the market is categorized into active tuberculosis and latent tuberculosis. As per therapy type, the market is categorized into first line therapy and second line therapy. According to distribution channel, the market is segregated into hospital pharmacies, drug stores & retail pharmacies, and online providers. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and Rest of Europe), Asia-Pacific (Japan, China, India, and Rest of Asia-Pacific), and LAMEA (Latin America, Middle East, and Africa).

Major key players that operate in the global tuberculosis treatment drugs market are: Lupin, Sanofi, Pfizer Inc., Fresenius SE & Co. KGaA (Fresenius Kabi), Johnson & Johnson, Teva Pharmaceuticals, Novartis AG, ANI Pharmaceuticals Inc., Otsuka Pharmaceutical Co., Ltd., and Macleods Pharmaceuticals Ltd.

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the tuberculosis treatment drugs market analysis from 2021 to 2031 to identify the prevailing tuberculosis treatment drugs market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the tuberculosis treatment drugs market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global tuberculosis treatment drugs market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Disease Type

Active Tuberculosis
Latent Tuberculosis

By Therapy Type

First Line Therapy
Second Line Therapy

By Distribution Channel

Hospital Pharmacies
Drug Stores and Retail Pharmacies
Online Providers

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
Asia-Pacific
- Japan
- China
- India
- Rest of Asia-Pacific
LAMEA
- Latin America
- Middle East And Africa

Key Market Players:

Lupin
Sanofi
Pfizer Inc.
FRESENIUS SE & Co. KGaA (Fresenius Kabi)
Johnson & Johnson
Novartis AG
Macleods Pharmaceuticals Ltd.
ANI Pharmaceuticals, Inc.
Otsuka Pharmaceutical Co., Ltd.
Teva Pharmaceutical Industries Ltd.

Product Code: A13238

CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
- 1.4.1. Primary research
- 1.4.2. Secondary research
- 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings
- 3.2.1. Top impacting factors
- 3.2.2. Top investment pockets
3.3. Porter's five forces analysis
- 3.3.1. Bargaining power of suppliers
- 3.3.2. Bargaining power of buyers
- 3.3.3. Threat of substitutes
- 3.3.4. Threat of new entrants
- 3.3.5. Intensity of rivalry
3.4. Market dynamics
- 3.4.1. Drivers
  - 3.4.1.1. Increase in R&D for tuberculosis drugs
  - 3.4.1.2. Growing initiatives from government organizations for tuberculosis awareness
  - 3.4.1.3. Rise in adoption of combinational therapy

3.4.2. Restraints
- 3.4.2.1. Adverse effects of Anti-Tuberculosis Drugs
- 3.4.2.2. Stringent Regulatory Guidelines for product approval

3.4.3. Opportunities
- 3.4.3.1. Growth opportunities in emerging markets

3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISEASE TYPE

4.1. Overview
- 4.1.1. Market size and forecast
4.2. Active Tuberculosis
- 4.2.1. Key market trends, growth factors and opportunities
- 4.2.2. Market size and forecast, by region
- 4.2.3. Market share analysis by country
4.3. Latent Tuberculosis
- 4.3.1. Key market trends, growth factors and opportunities
- 4.3.2. Market size and forecast, by region
- 4.3.3. Market share analysis by country

CHAPTER 5: TUBERCULOSIS TREATMENT DRUGS MARKET, BY THERAPY TYPE

5.1. Overview
- 5.1.1. Market size and forecast
5.2. First Line Therapy
- 5.2.1. Key market trends, growth factors and opportunities
- 5.2.2. Market size and forecast, by region
- 5.2.3. Market share analysis by country
5.3. Second Line Therapy
- 5.3.1. Key market trends, growth factors and opportunities
- 5.3.2. Market size and forecast, by region
- 5.3.3. Market share analysis by country

CHAPTER 6: TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISTRIBUTION CHANNEL

6.1. Overview
- 6.1.1. Market size and forecast
6.2. Hospital Pharmacies
- 6.2.1. Key market trends, growth factors and opportunities
- 6.2.2. Market size and forecast, by region
- 6.2.3. Market share analysis by country
6.3. Drug Stores and Retail Pharmacies
- 6.3.1. Key market trends, growth factors and opportunities
- 6.3.2. Market size and forecast, by region
- 6.3.3. Market share analysis by country
6.4. Online Providers
- 6.4.1. Key market trends, growth factors and opportunities
- 6.4.2. Market size and forecast, by region
- 6.4.3. Market share analysis by country

CHAPTER 7: TUBERCULOSIS TREATMENT DRUGS MARKET, BY REGION

7.1. Overview
- 7.1.1. Market size and forecast By Region
7.2. North America
- 7.2.1. Key trends and opportunities
- 7.2.2. Market size and forecast, by Disease Type
- 7.2.3. Market size and forecast, by Therapy Type
- 7.2.4. Market size and forecast, by Distribution Channel
- 7.2.5. Market size and forecast, by country
  - 7.2.5.1. U.S.
  - 7.2.5.1.1. Key market trends, growth factors and opportunities
  - 7.2.5.1.2. Market size and forecast, by Disease Type
  - 7.2.5.1.3. Market size and forecast, by Therapy Type
  - 7.2.5.1.4. Market size and forecast, by Distribution Channel
  - 7.2.5.2. Canada
  - 7.2.5.2.1. Key market trends, growth factors and opportunities
  - 7.2.5.2.2. Market size and forecast, by Disease Type
  - 7.2.5.2.3. Market size and forecast, by Therapy Type
  - 7.2.5.2.4. Market size and forecast, by Distribution Channel
  - 7.2.5.3. Mexico
  - 7.2.5.3.1. Key market trends, growth factors and opportunities
  - 7.2.5.3.2. Market size and forecast, by Disease Type
  - 7.2.5.3.3. Market size and forecast, by Therapy Type
  - 7.2.5.3.4. Market size and forecast, by Distribution Channel
7.3. Europe
- 7.3.1. Key trends and opportunities
- 7.3.2. Market size and forecast, by Disease Type
- 7.3.3. Market size and forecast, by Therapy Type
- 7.3.4. Market size and forecast, by Distribution Channel
- 7.3.5. Market size and forecast, by country
  - 7.3.5.1. Germany
  - 7.3.5.1.1. Key market trends, growth factors and opportunities
  - 7.3.5.1.2. Market size and forecast, by Disease Type
  - 7.3.5.1.3. Market size and forecast, by Therapy Type
  - 7.3.5.1.4. Market size and forecast, by Distribution Channel
  - 7.3.5.2. France
  - 7.3.5.2.1. Key market trends, growth factors and opportunities
  - 7.3.5.2.2. Market size and forecast, by Disease Type
  - 7.3.5.2.3. Market size and forecast, by Therapy Type
  - 7.3.5.2.4. Market size and forecast, by Distribution Channel
  - 7.3.5.3. UK
  - 7.3.5.3.1. Key market trends, growth factors and opportunities
  - 7.3.5.3.2. Market size and forecast, by Disease Type
  - 7.3.5.3.3. Market size and forecast, by Therapy Type
  - 7.3.5.3.4. Market size and forecast, by Distribution Channel
  - 7.3.5.4. Italy
  - 7.3.5.4.1. Key market trends, growth factors and opportunities
  - 7.3.5.4.2. Market size and forecast, by Disease Type
  - 7.3.5.4.3. Market size and forecast, by Therapy Type
  - 7.3.5.4.4. Market size and forecast, by Distribution Channel
  - 7.3.5.5. Spain
  - 7.3.5.5.1. Key market trends, growth factors and opportunities
  - 7.3.5.5.2. Market size and forecast, by Disease Type
  - 7.3.5.5.3. Market size and forecast, by Therapy Type
  - 7.3.5.5.4. Market size and forecast, by Distribution Channel
  - 7.3.5.6. Rest of Europe
  - 7.3.5.6.1. Key market trends, growth factors and opportunities
  - 7.3.5.6.2. Market size and forecast, by Disease Type
  - 7.3.5.6.3. Market size and forecast, by Therapy Type
  - 7.3.5.6.4. Market size and forecast, by Distribution Channel
7.4. Asia-Pacific
- 7.4.1. Key trends and opportunities
- 7.4.2. Market size and forecast, by Disease Type
- 7.4.3. Market size and forecast, by Therapy Type
- 7.4.4. Market size and forecast, by Distribution Channel
- 7.4.5. Market size and forecast, by country
  - 7.4.5.1. Japan
  - 7.4.5.1.1. Key market trends, growth factors and opportunities
  - 7.4.5.1.2. Market size and forecast, by Disease Type
  - 7.4.5.1.3. Market size and forecast, by Therapy Type
  - 7.4.5.1.4. Market size and forecast, by Distribution Channel
  - 7.4.5.2. China
  - 7.4.5.2.1. Key market trends, growth factors and opportunities
  - 7.4.5.2.2. Market size and forecast, by Disease Type
  - 7.4.5.2.3. Market size and forecast, by Therapy Type
  - 7.4.5.2.4. Market size and forecast, by Distribution Channel
  - 7.4.5.3. India
  - 7.4.5.3.1. Key market trends, growth factors and opportunities
  - 7.4.5.3.2. Market size and forecast, by Disease Type
  - 7.4.5.3.3. Market size and forecast, by Therapy Type
  - 7.4.5.3.4. Market size and forecast, by Distribution Channel
  - 7.4.5.4. Rest of Asia-Pacific
  - 7.4.5.4.1. Key market trends, growth factors and opportunities
  - 7.4.5.4.2. Market size and forecast, by Disease Type
  - 7.4.5.4.3. Market size and forecast, by Therapy Type
  - 7.4.5.4.4. Market size and forecast, by Distribution Channel
7.5. LAMEA
- 7.5.1. Key trends and opportunities
- 7.5.2. Market size and forecast, by Disease Type
- 7.5.3. Market size and forecast, by Therapy Type
- 7.5.4. Market size and forecast, by Distribution Channel
- 7.5.5. Market size and forecast, by country
  - 7.5.5.1. Latin America
  - 7.5.5.1.1. Key market trends, growth factors and opportunities
  - 7.5.5.1.2. Market size and forecast, by Disease Type
  - 7.5.5.1.3. Market size and forecast, by Therapy Type
  - 7.5.5.1.4. Market size and forecast, by Distribution Channel
  - 7.5.5.2. Middle East And Africa
  - 7.5.5.2.1. Key market trends, growth factors and opportunities
  - 7.5.5.2.2. Market size and forecast, by Disease Type
  - 7.5.5.2.3. Market size and forecast, by Therapy Type
  - 7.5.5.2.4. Market size and forecast, by Distribution Channel

CHAPTER 8: COMPETITIVE LANDSCAPE

8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Top player positioning, 2021

CHAPTER 9: COMPANY PROFILES

9.1. Lupin
- 9.1.1. Company overview
- 9.1.2. Key Executives
- 9.1.3. Company snapshot
- 9.1.4. Operating business segments
- 9.1.5. Product portfolio
- 9.1.6. Business performance
- 9.1.7. Key strategic moves and developments
9.2. Macleods Pharmaceuticals Ltd.
- 9.2.1. Company overview
- 9.2.2. Key Executives
- 9.2.3. Company snapshot
- 9.2.4. Operating business segments
- 9.2.5. Product portfolio
9.3. Sanofi
- 9.3.1. Company overview
- 9.3.2. Key Executives
- 9.3.3. Company snapshot
- 9.3.4. Operating business segments
- 9.3.5. Product portfolio
- 9.3.6. Business performance
9.4. Otsuka Pharmaceutical Co., Ltd.
- 9.4.1. Company overview
- 9.4.2. Key Executives
- 9.4.3. Company snapshot
- 9.4.4. Operating business segments
- 9.4.5. Product portfolio
- 9.4.6. Key strategic moves and developments
9.5. Pfizer Inc.
- 9.5.1. Company overview
- 9.5.2. Key Executives
- 9.5.3. Company snapshot
- 9.5.4. Operating business segments
- 9.5.5. Product portfolio
- 9.5.6. Business performance
9.6. FRESENIUS SE & Co. KGaA (Fresenius Kabi)
- 9.6.1. Company overview
- 9.6.2. Key Executives
- 9.6.3. Company snapshot
- 9.6.4. Operating business segments
- 9.6.5. Product portfolio
- 9.6.6. Business performance
9.7. Johnson & Johnson
- 9.7.1. Company overview
- 9.7.2. Key Executives
- 9.7.3. Company snapshot
- 9.7.4. Operating business segments
- 9.7.5. Product portfolio
- 9.7.6. Business performance
- 9.7.7. Key strategic moves and developments
9.8. Teva Pharmaceutical Industries Ltd.
- 9.8.1. Company overview
- 9.8.2. Key Executives
- 9.8.3. Company snapshot
- 9.8.4. Operating business segments
- 9.8.5. Product portfolio
- 9.8.6. Business performance
9.9. Novartis AG
- 9.9.1. Company overview
- 9.9.2. Key Executives
- 9.9.3. Company snapshot
- 9.9.4. Operating business segments
- 9.9.5. Product portfolio
- 9.9.6. Business performance
9.10. ANI Pharmaceuticals, Inc.
- 9.10.1. Company overview
- 9.10.2. Key Executives
- 9.10.3. Company snapshot
- 9.10.4. Operating business segments
- 9.10.5. Product portfolio
- 9.10.6. Business performance
- 9.10.7. Key strategic moves and developments